CASE REPORT
Nosocomial Neonatal Meningitis with Acinetobacter Baumannii on Myelomeningocele: A Real Therapeutic Challenge
Adil Fouad1, *, Fatiha Bennaoui1, Nadia El Idrissi Slitine1, Nabila Soraa2, FMR Maoulainine1
Article Information
Identifiers and Pagination:
Year: 2018Volume: 10
First Page: 43
Last Page: 46
Publisher Id: TOIDJ-10-43
DOI: 10.2174/1874279301810010043
Article History:
Received Date: 10/3/2018Revision Received Date: 6/6/2018
Acceptance Date: 13/6/2018
Electronic publication date: 26/6/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Imipenem-resistant Acinetobacter baumannii meningitis is a hospital-acquired infection, the treatment of which constitutes a real therapeutic challenge. In this article, together with a review of the literature, we report two cases of imipenem-resistant Acinetobacter baumannii neonatal meningitis following ruptured myelomeningocele, treated with intravenous colistin with favorable results. In recent years, Acinetobacter baumannii has become a more and more commonly described pathogen in hospital-acquired infections. However, the cases of meningitis are mainly postoperative and are still not quite frequently described in the literature. Colistin appears to be preferably administered intravenously at a dose of 100.000 IU/kg/day.